Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

Date : 05/15/2019 @ 10:01PM
Source : Edgar (US Regulatory)
Stock : Angiogenex, Inc. (PC) (AGGX)
Quote : 0.247  0.0 (0.00%) @ 12:56PM

Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

 



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SEC FILE NUMBER

000-26181

FORM 12b-25

CUSIP NUMBER

03475U 30 1


NOTIFICATION OF LATE FILING



(Check one): [  ]Form 10-K   [  ]Form 20-F   [  ]Form 11-K   [X]Form 10-Q   [  ]Form N-SAR   [  ]Form N-CSR


For Period Ended:   March 31, 2019

__Transition Report on Form 10-K

__Transition Report on Form 20-F

__Transition Report on Form 11-K

__Transition Report on Form 10-Q

__Transition Report on Form N-SAR

For the Transition Period Ended:  


If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:



PART I – REGISTRANT INFORMATION


ANGIOGENEX, INC.

Full Name of Registrant


_________________________

Former Name if Applicable


425 MADISON AVE., SUITE 902

Address of Principal Executive Office (Street and Number)


NEW YORK, NY 10017

City, State and Zip Code


PART II – RULES 12b-25(b) and (c)


If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)


X

(a)

The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense

(b)

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

(c)

The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.


PART III – NARRATIVE


State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.


The Registrant's quarterly report on Form 10-Q cannot be filed within the prescribed time period due to the accountants requiring additional time to prepare the financial statements of the Registrant.



- 1 -




PART IV – OTHER INFORMATION


(1)

Name and telephone number of person to contact in regard to this notification


Martin Murray

(347)

468-6799

(Name)

(Area Code)

(Telephone Number)


(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed?  If answer is no, identify report(s).  Yes X  No _

(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?  Yes _  No X


If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

  

  


AngioGenex, Inc.

(Name of Registrant as Specified in Charter)


has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.


Date:  

May 15, 2019

By:

/s/ Martin Murray

Martin Murray

Chief Financial Officer and Treasurer


INSTRUCTION:  The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.


ATTENTION:  Intentional misstatements or omissions of fact constitute Federal Criminal Violations (see 18 U.S.C. 1001).



- 2 -



Angiogenex, Inc. (PC) (USOTC:AGGX)
Historical Stock Chart

1 Year : From Aug 2018 to Aug 2019

Click Here for more Angiogenex, Inc. (PC) Charts.

Angiogenex, Inc. (PC) (USOTC:AGGX)
Intraday Stock Chart

Today : Monday 19 August 2019

Click Here for more Angiogenex, Inc. (PC) Charts.

Latest AGGX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.